Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Other operating expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Danaher

Danaher Corp. operates as a medical company, which designs, manufactures, and markets professional, medical, industrial, and commercial products and services. It operates through the following segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, to understand the causes of disease, identify new therapies and test new drugs and vaccines. The Diagnostics segment is composed of analytical instruments, reagents, consumables, software, and services that hospitals, physicians' offices, reference laboratories, and other critical care settings use to diagnose disease and make treatment decisions. The Environmental & Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Danaher exceeds Q1 expectations, eyes growth in China market

Danaher's Q1 performance showcased resilience and strategic focus amidst revenue challenges.
The company's strengths in operational efficiency and strategic initiatives position it well for future growth.
Challenges in certain segments highlight the need for adaptive strategies and market diversification.
Opportunities in China's market recovery and operational improvements offer avenues for sustained growth.

Danaher reports resilient Q2 performance amid COVID-19 challenges

Danaher navigated Q2 2023 with resilience amidst COVID-19 challenges, showcasing strong financial performance and strategic focus. While facing revenue declines in certain segments, the company remains confident in its ability to create shareholder value and improve human health. Capital deployment, inventory management, and market alignment present opportunities for future growth.

Danaher reports Q3 revenue decline, eyes growth in diagnostics market

Danaher's Q3 performance showed revenue declines in key segments, but strategic moves like spin-offs and acquisitions indicate a focus on long-term growth. Challenges in China and revenue projections for the year present short-term hurdles, while opportunities in drug development and diagnostics offer potential for future expansion.

Danaher reports solid 2023 performance, anticipates gradual growth in 2024

Danaher Corporation's 2023 performance showcased strong full-year sales and operating profit margin, but the fourth quarter saw a decline in core revenue. The company is focused on enhancing its portfolio and strengthening its growth trajectory, with expectations for improved growth in the second half of 2024. Challenges include the need for gradual improvement in demand and the pace of recovery in different geographies.

Danaher beats Q1 expectations, eyes growth in Diagnostics segment

Danaher's Q1 2024 performance exceeded expectations, driven by strong Diagnostics segment growth.
While facing challenges in bioprocessing and margin expectations, the company remains focused on long-term sustainability.
Opportunities lie in anticipated growth in Diagnostics and bioprocessing segments, with a focus on innovation and recurring revenue.
Continuous monitoring of market trends and global capabilities position Danaher for future success.

Danaher beats Q2 expectations, eyes growth amid revenue challenges

Danaher Corporation delivered a strong performance in Q2 2024, surpassing revenue, earnings, and cash flow expectations, driven by bioprocessing and Cepheid's success.
While facing challenges such as core revenue declines in the biotechnology segment, the company maintains a solid financial position with strong free cash flow.
Opportunities lie in leveraging positive momentum in key segments, expanding market share, and enhancing sustainability efforts to drive future growth and profitability.
Overall, Danaher's strategic focus on operational efficiency and growth areas positions it well to navigate challenges and capitalize on opportunities in the evolving market landscape.

Danaher surpasses Q3 expectations, eyes China stimulus for growth

Danaher's Q3 performance exceeded expectations, driven by strong results in biotechnology and Cepheid's core revenue growth.
While facing challenges in China market dynamics and core revenue declines in certain segments, the company remains optimistic about future growth.
Opportunities lie in leveraging China's stimulus for 2025 outlook and strategic M&A activities to fuel long-term growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments: Biotechnology, Life Sciences, Diagnostics, and Environmental and Applied Solutions. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of tools, consumables, and services. The Life Sciences segment offers a range of instruments and consumables to study the basic building blocks of life, including DNA and RNA. The Diagnostics segment offers clinical instruments, reagents, consumables, software, and services used to diagnose disease and make treatment decisions. The Environmental and Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

Coty

Foot Locker

Biglari Hlds

Biohaven Pharmaceutical Hld

Stoke Therapeutics Inc

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can be an encouraging signal for potential investors, particularly when there is uncertainty in the markets, as there was before and after the elections and as the pandemic worsens.

Notable Insider Buys in the Past Week: Biglari, Coty, Danaher, Foot Locker And More

Science and technology company Danaher Corporation (NYSE: DHR) boasts a high-quality and defensive portfolio that has become "less compelling to own" ahead of a cyclical recovery into 2021, according to RBC Capital Markets. The Analyst: Deane Dray downgraded Danaher from Outperform to Sector Perform with a price target lowered from $273 to $234.

RBC Downgrades Danaher, Says Defensive Portfolio 'Less Compelling To Own'

Deere & Company

FedEx

Microsoft

NVIDIA

Target

Thermo Fisher Scientific

It will be prudent to invest in large-cap stocks with a favorable Zacks Rank that are members of any of the three large-cap indexes. These are DHR, UPS, NVDA, MSFT, TGT, TMO, DE, FDX.

Enjoy Thanksgiving with a Wall Street Bonanza

Danaher (DHR) reported earnings 30 days ago. What's next for the stock?

Danaher (DHR) Down 3.5% Since Last Earnings Report: Can It Rebound?

WASHINGTON, Nov. 16, 2020 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that Executive Vice President and Chief Financial Officer, Matt McGrew, will be presenting at the Wolfe Research Healthcare Conference on Thursday, November 19, 2020 at 12:00 p.m. ET. The audio will be...

Danaher To Present At Wolfe Research Healthcare Conference

Abbott Labs

Estee Lauder

Johnson & Johnson

Coca-Cola

McDonald's

Mondelez

PepsiCo

Procter & Gamble

Walmart

In this article we present the list of Top 10 Stocks Billionaire Ray Dalio Just Bought. Click to skip ahead and see the  Top 5 Stocks Billionaire Ray Dalio Just Bought .

Top 10 Stocks Billionaire Ray Dalio Just Bought

Danaher (DHR) to benefit from healthy growth opportunities in Life Sciences and Diagnostics segments, acquired assets and shareholders-friendly policies.

5 Reasons Why Danaher (DHR) Stock is Worth Investing in Now

WASHINGTON, Nov. 10, 2020 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher" or "the Company") today published its 2020 Sustainability Report, highlighting key environmental, social and governance developments at the Company and announcing new diversity and environmental goals....

Danaher Releases 2020 Sustainability Report

Illinois Tool Works

Pentair

Axalta Coating Systems

The recent outperformances of these very different companies reveal much about which investment themes are working at this point in 2020.

These 4 Top Stocks Have Surpassed Management's Highest Expectations

Advanced Micro Devices

Cognizant Technology Solutions

QUALCOMM

Rockwell Automation

Virgin Galactic

The 2020s will see machine data become intelligence, intelligence become automation, and automation spread from factories to cities and your wrist. The post 7 5G Stocks to Buy for the Future of the Machine Internet appeared first on InvestorPlace.

7 5G Stocks to Buy for the Future of the Machine Internet

The company's diagnostic tests and life sciences research tools are being extensively used in the fight against the pandemic.

Danaher Is One of the Big Winners From COVID-19

Danaher's last quarter earnings beat expected results on the bottom and top line and with a good gain over last year's results when the dividend was increased to 6%. Danaher's three-year forward CAGR of 13% is good and will give you long-term growth with increasing demand for more medical and industrial products as the economy and population increases.

Danaher: Great Gain In Revenue From Pandemic

Salesforce

Shopify

Investors focused on tech growth stocks may want to consider the following companies, as their quarterly revenue and net income have had strong growth on a year-over-year basis.

3 Tech Growth Stocks to Consider

DHR stock is at the heart of the Machine Internet, using sensors and networks to transform how other things are made. The post Buy Danaher Stock and Let It Work For You appeared first on InvestorPlace.

Buy Danaher Stock and Let It Work For You

Asbury Automotive Group

National Beverage

Top Ranked Momentum Stocks to Buy for October 23rd

Danaher Corp (NYSE: DHR) said on Thursday that its sales and profit in the fiscal third quarter came in better than expected. Shares of the company jumped more than 3% on market open.

Danaher Corp's revenue climbs to £4.49 billion in the fiscal third quarter

Danaher Corporation (DHR) CEO Rainer Blair on Q3 2020 Results - Earnings Call Transcript

Danaher's (DHR) Q3 results reflect growth in Life Sciences and Diagnostics segments' sales, contribution from Cytiva, and operating margin rise. Core Q4 sales are likely to grow in high-single digits.

Danaher (DHR) Q3 Earnings Beat, Rise Y/Y on Sales Growth

Shares of Danaher (NYSE:DHR) fell 1% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share increased 48.28% over the past year to $1.72, which beat the estimate of $1.36.

Recap: Danaher Q3 Earnings

Danaher earnings beat third-quarter views, with Covid-19 tests fueling growth. DHR stock is trading at record highs.

Danaher Earnings Beat With DHR Stock At Record Highs

WASHINGTON, Oct. 22, 2020 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended October 2, 2020. All results in this release reflect only continuing operations unless otherwise noted. For the third quarter 2020, net earnings were...

Danaher Reports Third Quarter 2020 Results

Danaher (DHR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Danaher (DHR)

Altra Industrial Motion

Mattel

Penske Automotive Group

PulteGroup

Five companies namely, Danaher (DHR), PulteGroup (PHM), Penske Automotive (PAG), Mattel (MAT) and Altra Industrial Motion (AIMC) with a favorable Zacks Rank are poised to beat earnings estimates this week.

5 High-Flying Stocks With Room to Run on Q3 Earnings This Week

Does Danaher (DHR) have what it takes to be a top stock pick for momentum investors? Let's find out.

Danaher (DHR) is a Great Momentum Stock: Should You Buy?

Danaher's (DHR) Q3 results are expected to reflect a healthy demand for products in Life Sciences and Diagnostics segments. Also, Cytiva is anticipated to have aided core sales.

News for Danaher Stock (DHR)